Isomorphic Labs, a drug discovery startup spun from Google DeepMind, has announced that it has raised $600 million from external funding for the first round. The pay raise was led by Thrive Capital, with participation from Google Ventures and Alphabet, which previously supported the company.
Isomorphic uses fresh capital injections to grow your team and speed up research and development. Hassavis recently suggested that Isomorphic expects to have AI-designed drugs in clinical trials by the end of 2025.
Founded in 2021, Isomorphic was launched as a spin-off from DeepMind, Alphabet’s AI research unit. After signing a $3 billion deal with Pharma giant Lily and Novartis last year, we took up the startup.
“We’re committed to providing a range of services to our customers,” said Demis Hassabis, Founder and CEO of Isomorphic Labs. “This funding is an important step towards our mission to further turbocharge the development of the next generation of AI drug design engines, helping us move our own programs into clinical development, and to solve all diseases with the help of AI.”
This effort is led by Demis Hassabis. Hassavis is at the helm of both companies and brought years of experience to the table in AI research.
One of the biggest breakthroughs of comparable morphology to date is the study at Alphafold, a tool that can predict the structure of almost any known protein. Last May, the company released a third version of the model. This is the construction of research that has already gained deep awareness from the scientific community.
“At Thrive, we aim to invest in a category-defined company that has been singly convicted, which has led us to an equal lab,” said Joshua Kushner, founder and CEO of Thrive Capital. “We believe that Isomorphic has acquired an unusual position defining a new era of drug discovery and design, and is deeply inspired by their mission and the extraordinary advances they have made so far.”
Why is it important?
Big Tech has not slowed down with AI, and the competition to lead AI to healthcare is intensifying. Investors are using machine learning to tackle drug research, and have placed huge bets on startups where AI could actually move needles in the short term.
The company is based in London and is becoming one of the most viewed names in AI-driven drug development.
🚀Want to introduce the story?
Submit your stories to TechStartUps.com in front of thousands of founders, investors, PE companies, tech executives, decision makers and tech leaders.
Please attract attention
Source link
